CIPO Patents = 1

Forward Citations = 22

Loading Chart...

2 inventors (with patents filed for the assignee):

Thomas E Jenkins (8 out of 61 patents)

Craig Husfeld (1 out of 85 patents)

8 patents: Sort by Forward Citations

1. 11318132 - Diversion-resistant opioid formulations (2022-05-03),

2. 11197933 - Polysubunit opioid prodrugs resistant to overdose and abuse (2021-12-14),

3. 11154549 - Opioid compositions resistant to overdose and abuse (2021-10-26),

4. 11129825 - Polysubunit opioid prodrugs resistant to overdose and abuse (2021-09-28),

5. 10335406 - Opioid compositions resistant to overdose and abuse (2019-07-02),

6. 10314839 - Diversion-resistant opioid formulations (2019-06-11),

7. 10251878 - Polysubunit opioid prodrugs resistant to overdose and abuse (2019-04-09),

8. 9808452 - Polysubunit opioid prodrugs resistant to overdose and abuse (2017-11-07),

Elysium Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for a wide range of diseases. With a team of experienced scientists and a robust pipeline of potential treatments, Elysium is dedicated to improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

8 Patents

#45 in Akron, OH

#1,388 in Ohio

#34,918 in US

Akron, OH, United States of America

Elysium Therapeutics, Inc.

Forward Citations = 22

2 inventors:

Thomas E Jenkins (8 out of 61 patents)

Craig Husfeld (1 out of 85 patents)

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com